ANIP

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +1.66
Percentage change 2.61	%

Peers: AMGN REGN VRTX BIIB GILD ILMN BMRN INCY NBIX UTHR

| Held by: IJR VTI IWM VXF IWO IJT SPSM PJP VTWO SLYG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.27	Insider Own	16.82%	Shs Outstand	21.66M	Perf Week	-1.05%
Market Cap	1.41B	Forward P/E	9.44	EPS next Y	6.91	Insider Trans	-0.47%	Shs Float	18.02M	Perf Month	5.35%
Enterprise Value	1.91B	PEG	-	EPS next Q	1.37	Inst Own	94.42%	Short Float	11.17%	Perf Quarter	-4.12%
Income	-24.24M	P/S	2.10	EPS this Y	25.87%	Inst Trans	5.86%	Short Ratio	5.29	Perf Half Y	19.87%
Sales	674.07M	P/B	3.38	EPS next Y	5.55%	ROA	-2.05%	Short Interest	2.01M	Perf YTD	17.98%
Book/sh	19.32	P/C	9.10	EPS next 5Y	14.24%	ROE	-5.19%	52W High	77.00 -15.30%	Perf Year	2.42%
Cash/sh	7.17	P/FCF	21.21	EPS past 3/5Y	32.54% -	ROIC	-2.30%	52W Low	52.50 24.23%	Perf 3Y	116.10%
Dividend Est.	-	EV/EBITDA	24.68	Sales past 3/5Y	41.66% 24.36%	Gross Margin	48.07%	Volatility	2.90% 2.85%	Perf 5Y	107.11%
Dividend TTM	-	EV/Sales	2.83	EPS Y/Y TTM	-173.36%	Oper. Margin	0.19%	ATR (14)	1.95	Perf 10Y	3.02%
Dividend Ex-Date	-	Quick Ratio	1.98	Sales Y/Y TTM	30.26%	Profit Margin	-3.60%	RSI (14)	54.91	Recom	1.43
Dividend Gr. 3/5Y	- -	Current Ratio	2.66	EPS Q/Q	-16.91%	SMA20	2.04%	Beta	0.61	Target Price	81.00
Payout	-	Debt/Eq	1.55	Sales Q/Q	43.43%	SMA50	1.32%	Rel Volume	0.54	Prev Close	63.56
Employees	897	LT Debt/Eq	1.52	Earnings	May 09 BMO	SMA200	7.52%	Avg Volume	380.38K	Price	65.22
IPO	May 12, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	22.97% 9.13%	Trades		Volume	203,912	Change	2.61%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-14-25	Initiated	Jefferies	Buy	$80
Mar-12-25	Initiated	JP Morgan	Overweight	$85
Dec-11-24	Initiated	Leerink Partners	Outperform	$80
Oct-11-24	Initiated	Piper Sandler	Overweight	$68
Mar-15-24	Initiated	CapitalOne	Overweight	$80
Aug-22-23	Reiterated	H.C. Wainwright	Buy	$60 → $73
Mar-01-23	Initiated	Guggenheim	Buy	$55
Sep-07-22	Initiated	H.C. Wainwright	Buy	$50
Nov-02-21	Initiated	Truist	Buy	$70
May-07-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-19	Initiated	Guggenheim	Buy
May-10-19	Downgrade	Raymond James	Strong Buy → Outperform	$73 → $82
Oct-16-17	Reiterated	Canaccord Genuity	Buy	$60 → $66
Jul-31-17	Initiated	Canaccord Genuity	Buy	$60
Feb-22-17	Downgrade	ROTH Capital	Buy → Neutral
Jun-23-16	Initiated	Raymond James	Strong Buy	$68
May-24-16	Downgrade	Standpoint Research	Buy → Hold
Nov-13-15	Initiated	Standpoint Research	Buy	$54
Sep-28-15	Upgrade	ROTH Capital	Neutral → Buy	$67 → $60
Aug-05-15	Reiterated	Oppenheimer	Outperform	$74 → $65

Show Previous Ratings

Today 06:50AM	ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th (GlobeNewswire)
Jun-30-25 07:41AM	The Top 5 Analyst Questions From ANI Pharmaceuticals's Q1 Earnings Call (StockStory)
Jun-19-25 11:35PM	ANI Pharmaceuticals (NASDAQ:ANIP) Q1 Earnings: Leading The Generic Pharmaceuticals Pack (StockStory)
Jun-12-25 07:00AM	ANI Pharmaceuticals Announces Presentation of New Preclinical Data (GlobeNewswire)
Jun-04-25 10:43AM	ANIP Q1 CY2025 Earnings Call: Generics, Rare Disease Drive Growth; Retina Headwinds Noted (StockStory)
04:30PM	Loading…
May-27-25 04:30PM	ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-26-25 12:01AM	3 Reasons to Avoid ANIP and 1 Stock to Buy Instead (StockStory)
May-23-25 10:10AM	ANI Pharmaceuticals initiates Phase IV trial of gel for acute gout flares (Clinical Trials Arena)
May-22-25 06:50AM	ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin Gel for the Treatment of Acute Gout Flares (GlobeNewswire)
May-12-25 06:30PM	ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ (GlobeNewswire) -6.03%
12:45PM	ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
May-10-25 03:02AM	ANI Pharmaceuticals Inc (ANIP) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
May-09-25 12:39PM	Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y (Zacks) -7.31%
12:25PM	Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up (Zacks)
12:07PM	Cortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact (Benzinga)
09:40AM	Loading…
09:40AM	Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? (Zacks)
09:30AM	Compared to Estimates, ANI (ANIP) Q1 Earnings: A Look at Key Metrics (Zacks)
09:08AM	Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down (Zacks)
08:48AM	PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates (Zacks)
08:10AM	ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates (Zacks)
07:10AM	ANI: Q1 Earnings Snapshot (Associated Press Finance)
06:50AM	ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance (GlobeNewswire)
May-08-25 05:15PM	Pacira (PCRX) Q1 Earnings Surpass Estimates (Zacks)
12:13PM	Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised (Zacks)
12:07PM	Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
09:55AM	IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates (Zacks)
09:27AM	ANI Pharmaceuticals Inc (ANIP) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
May-07-25 12:42PM	Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y (Zacks)
12:13PM	HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View (Zacks)
12:09PM	ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down (Zacks)
08:59AM	Loading…
08:59AM	BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates (Zacks)
May-05-25 12:12PM	ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards? (Zacks)
11:12AM	DENTSPLY SIRONA to Post Q1 Earnings: What's in Store for the Stock? (Zacks)
09:15AM	ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue? (Zacks)
07:00AM	ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model (GlobeNewswire)
May-02-25 01:40PM	Cigna Q1 Earnings Beat Estimates on Evernorth Health Strength (Zacks)
01:20PM	Viatris Q1 Earnings Release: What's in Store for the Stock? (Zacks)
11:05AM	Should You Buy, Sell, or Hold FMS Stock Before Q1 Earnings? (Zacks)
10:00AM	ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Apr-29-25 01:21PM	Community Health Q1 Earnings Top on Rising Patient Volumes, Stock Up 8% (Zacks)
10:08AM	Universal Health Q1 Earnings Beat on Strong Acute Care Admissions (Zacks)
08:40AM	NeoGenomics (NEO) Reports Break-Even Earnings for Q1 (Zacks)
Apr-28-25 11:22AM	Should You Buy, Sell, or Hold GE Healthcare Before Q1 Earnings? (Zacks)
09:12AM	Here's How Charles River is Placed Just Ahead of Q1 Earnings (Zacks)
08:45AM	GYN Surgical Division Likely to Drive Hologic's Q2 Earnings (Zacks)
05:05AM	Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest (StockStory)
Apr-27-25 01:09PM	1 of Wall Street's Favorite Stock to Target This Week and 2 to Keep Off Your Radar (StockStory)
Apr-25-25 12:45PM	3 Reasons Growth Investors Will Love ANI (ANIP) (Zacks)
10:41AM	GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline (Zacks)
08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
07:06AM	Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season? (Zacks)
Apr-24-25 02:20PM	Merck Q1 Earnings & Sales Beat Estimates, '25 EPS Outlook Cut (Zacks)
11:54AM	BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook (Zacks)
08:41AM	Zacks.com featured highlights include Heritage Insurance, Marex, Kingstone, ANI Pharmaceuticals and HCI (Zacks)
06:31AM	Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips (Zacks)
Apr-23-25 09:40AM	Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? (Zacks)
09:02AM	Zacks.com featured highlights include ANI Pharmaceuticals, Heritage Insurance, Avista and Exelon (Zacks)
08:29AM	Buy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes Continue (Zacks)
06:05AM	5 Stocks With Recent Price Strength Amid Tariff-Led Volatility (Zacks)
Apr-22-25 08:22AM	4 Stocks Trading Near 52-Week High With Room to Rise Further (Zacks)
Apr-21-25 10:16AM	Danaher Gears Up to Post Q1 Earnings: Is a Beat in Store? (Zacks)
Apr-17-25 09:15AM	ANI Pharmaceuticals, Inc. (ANIP) Soars to 52-Week High, Time to Cash Out? (Zacks)
Apr-16-25 07:32AM	SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies (Zacks)
Apr-15-25 08:17AM	BMY Down on Heart Drug Camzyos Failure in Late-Stage Study (Zacks)
05:10AM	ANI Pharmaceuticals (ANIP): Buy, Sell, or Hold Post Q4 Earnings? (StockStory)
Apr-11-25 01:18PM	Bayer Obtains Full FDA Approval for Oncology Drug Vitrakvi (Zacks)
Apr-10-25 01:07PM	Vaxcyte Stock Plummets 56% in a Month: Here's the Reason (Zacks)
01:03PM	IBD 50 Stock Flashes 'Golden Cross' But Massive Risk Looms (Investor's Business Daily)
07:00AM	VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study (Zacks)
Apr-09-25 01:44PM	BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo (Zacks)
12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP) (Zacks)
12:10PM	Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report? (Zacks)
10:58AM	RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks (Zacks)
08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
06:50AM	ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET (GlobeNewswire)
Apr-08-25 06:55AM	VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe (Zacks) -5.88%
06:46AM	FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug (Zacks)
04:53AM	Zacks.com featured highlights ANI Pharmaceuticals, Expand Energy, Avista Corp and Contango ORE (Zacks)
Apr-07-25 09:40AM	Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:23AM	Tariff Woes? Play Safe With 4 Low-Beta Stocks: ANIP, EXE, AVA & CTGO (Zacks)
Apr-04-25 07:29AM	SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy (Zacks)
Apr-03-25 10:14AM	BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study (Zacks)
08:42AM	Is the Options Market Predicting a Spike in ANI Pharmaceuticals (ANIP) Stock? (Zacks)
Apr-02-25 01:38PM	GRI Stock Down on Public Offering Despite Encouraging IPF Study Data (Zacks)
10:18AM	LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? (Zacks)
08:35AM	Zacks.com featured highlights include HIS, ANI Pharmaceuticals, Pediatrix Medical, Fresenius Medical Care and LendingTree (Zacks)
Apr-01-25 03:00PM	CHMP Issues Positive Opinion for Label Expansion of BMY's Opdivo (Zacks)
10:50AM	CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal (Zacks)
09:42AM	5 Relative Price Strength Stocks to Navigate Today's Market (Zacks)
08:25AM	5 High Earnings Yield Value Picks to Counter Market Uncertainty (Zacks)
Mar-31-25 04:30PM	ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference (GlobeNewswire)
Mar-30-25 06:50AM	abrdn U.S. Small Cap Equity Fund Q4 2024 Commentary (Seeking Alpha)
Mar-28-25 12:00PM	abrdn Focused U.S. Small Cap Active ETF Q4 2024 Commentary (Seeking Alpha)
11:20AM	FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda (Zacks)
Mar-26-25 07:58AM	GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection (Zacks)
02:06AM	FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised) (Zacks)
Mar-25-25 08:11AM	5 Top-Ranked Mid-Cap Stocks to Buy for a Stellar Portfolio (Zacks)
07:56AM	FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Zacks)
Mar-24-25 12:45PM	Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
09:55AM	Wall Street Analysts Think ANI (ANIP) Could Surge 26.83%: Read This Before Placing a Bet (Zacks)

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jun 13 '25	Sale	61.37	400	24,548	79,345	Jun 16 05:24 PM
Gutwerg Ori	SVP, GENERICS	May 15 '25	Sale	60.07	881	52,922	89,897	May 16 04:57 PM
Mutz Christopher	HEAD OF RARE DISEASE	May 14 '25	Sale	60.45	4,000	241,800	107,317	May 15 08:10 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	May 13 '25	Sale	62.20	400	24,880	79,745	May 13 04:29 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	May 09 '25	Sale	76.83	700	53,781	631,920	May 13 04:21 PM
Shanmugam Muthusamy	Officer	May 09 '25	Proposed Sale	76.77	700	53,740		May 12 08:50 AM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Apr 14 '25	Sale	68.96	400	27,584	80,145	Apr 14 04:17 PM
Davis Krista	SVP, CHIEF HR OFFICER	Mar 19 '25	Sale	65.00	1,866	121,290	64,659	Mar 20 04:14 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Mar 13 '25	Sale	63.33	400	25,332	80,545	Mar 14 05:28 PM
Davis Krista	SVP, CHIEF HR OFFICER	Mar 07 '25	Sale	60.86	1,000	60,860	66,525	Mar 10 08:28 PM
Gutwerg Ori	SVP, GENERICS	Mar 05 '25	Option Exercise	31.49	300	9,447	99,476	Mar 07 04:09 PM
Gutwerg Ori	SVP, GENERICS	Mar 05 '25	Sale	60.00	5,384	323,049	94,092	Mar 07 04:09 PM
Davis Krista	SVP, CHIEF HR OFFICER	Feb 21 '25	Sale	60.20	1,000	60,200	68,624	Feb 24 04:33 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Feb 13 '25	Sale	59.54	400	23,816	83,478	Feb 18 08:12 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jan 13 '25	Sale	53.92	400	21,568	55,588	Jan 13 04:15 PM
CAREY STEPHEN P.	SVP & CFO	Dec 17 '24	Sale	55.79	7,500	418,425	154,468	Dec 18 05:59 PM
CAREY STEPHEN P.	Officer	Dec 17 '24	Proposed Sale	55.25	7,500	414,375		Dec 17 05:35 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Dec 13 '24	Sale	56.24	250	14,060	55,988	Dec 16 04:20 PM
Davis Krista	SVP, CHIEF HR OFFICER	Dec 11 '24	Sale	60.00	1,000	60,000	49,059	Dec 12 05:08 PM
Lalwani Nikhil	PRESIDENT & CEO	Nov 26 '24	Option Exercise	29.00	30,000	870,000	403,859	Nov 27 05:38 PM
Lalwani Nikhil	PRESIDENT & CEO	Nov 26 '24	Sale	57.99	33,481	1,941,442	370,378	Nov 27 05:38 PM
Lalwani Nikhil	Officer	Nov 26 '24	Proposed Sale	57.99	33,481	1,941,484		Nov 26 07:44 PM
Mutz Christopher	HEAD OF RARE DISEASE	Nov 15 '24	Sale	57.70	6,500	375,050	76,777	Nov 18 04:03 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Nov 13 '24	Sale	61.36	250	15,340	56,238	Nov 14 04:16 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Oct 14 '24	Sale	57.19	250	14,298	56,488	Oct 15 05:57 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Sep 13 '24	Sale	56.82	250	14,205	56,738	Sep 16 04:50 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Aug 13 '24	Sale	59.62	250	14,905	56,988	Aug 14 08:29 AM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 18 '24	Sale	62.00	2,743	170,066	632,620	Jul 19 05:30 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 16 '24	Sale	64.27	22,000	1,413,940	649,620	Jul 17 07:07 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 17 '24	Sale	63.16	14,257	900,472	635,363	Jul 17 07:07 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 15 '24	Sale	63.38	11,000	697,180	671,620	Jul 17 07:07 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jul 12 '24	Sale	64.91	250	16,228	58,981	Jul 15 04:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANI Pharmaceuticals Inc

Upgrade your FINVIZ experience